Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Billionaire Ray Dalio’s Top Picks Outshined By His Fund’s Performance

Page 1 of 2

Ray Dalio‘s Bridgewater Associates might not have fared so well in terms of its long equity positions, which returned 0.6% in the first quarter according to our returns metric, which is based on the performance of the fund’s 329 long positions at the beginning of the quarter, in companies with a market cap exceeding $1 billion. However, Bridgewater’s macro strategy fund, Bridgewater Pure Alpha II managed to return 14.5% over the quarter. Dalio’s bets on macroeconomic trends which were based on a strengthening dollar and a delay in the Fed’s interest rate hike paid off well for the world’s largest hedge fund firm, which has nearly $169 billion in assets under management.


Dalio’s flagship fund, the All Weather Fund, which was comprised of nearly $80 billion in assets in 2014, gained 8.6% net of fees last year while the average hedge fund returns hovered around 2.5%. Returns from the big Pure Alpha fund stood at 3.6% net of fees for 2014, which was a remarkable feat in itself since many macro funds struggled during that year. The market value of Bridgewater’s equity portfolio stood at $12.53 billion towards the end of 2014 with ETFs and index funds comprising more than 50% of this value. This is also the reason why, according to our methodology, the returns of Bridgewater’s stock holdings were closer to the S&P 500 ETF (SPY)’s 0.9% returns during the first quarter. Among the fund’s top stock holdings were Apple Inc. (NASDAQ:AAPL), Gilead Sciences, Inc. (NASDAQ:GILD), Microsoft Corporation (NASDAQ:MSFT), Intel Corporation (NASDAQ:INTC) and International Business Machines Corp. (NYSE:IBM).

Most investors don’t have enough time to do in-depth analysis on each stock they want to include in their portfolios. Professional investors like Ray Dalio, spend weeks conducting due diligence on each company and spend millions obtaining information and paying the salaries of Ivy League-educated analysts. That’s why we have always believed that imitating the stock picks of hedge funds and billionaires is an excellent short cut we can take. It doesn’t cost an arm and a leg either. We analyzed the historical stock picks of these investors and our research revealed that the small-cap picks of hedge funds performed better than the market and much better than their large-cap picks. A portfolio of the 15 most popular small-caps among several hedge funds outperformed the S&P 500 Total Return Index by 95 basis points per month between 1999 and 2012. The exceptional results of this strategy got even better in the forward tests we have been conducting since the end of August 2012. The most popular small-cap stocks among hedge funds beat the market by more than 79 percentage points since then (see the details here).

Despite being one of Dalio’s top picks, Apple Inc. (NASDAQ:AAPL) constituted only 0.23% of the fund’s portfolio value. The stake stood at 259,500 shares valued at $28.64 million. Apple’s stock gained the most among the above list of companies, by 13.17% over the quarter. The tech company’s new gadget, Apple Watch has been met with mixed expectations among analysts, with some like Raymond James cutting their rating of the company to ‘Market Perform’ from ‘Outperform’, while others including Canaccord Genuity have reiterated their ‘Buy’ rating for Apple Inc. (NASDAQ:AAPL), with that analyst raising its price target to $150 from $145. Among over 700 hedge funds that we track, Carl Icahn’s Icahn Capital LP held the highest stake in the $734.15 billion company.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!